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Prostate Cancer: Developing Novel Approaches to
Castration-Sensitive Disease
Edoardo Francini, MD1,2; and Mary-Ellen Taplin, MD2
Although androgen-deprivation therapy (ADT) remains the mainstay of castration-sensitive prostate cancer (CSPC) therapy, the dis-
ease’s heterogeneity and the limited duration of the response have chaperoned the introduction of chemotherapy and the investiga-
tion of novel hormonal targeted agents in this setting. Combinations of ADT plus chemotherapy or novel hormonal therapies are
being tested at various stages of CSPC with promising results. Furthermore, immunotherapy and experimental drugs are also being
actively investigated in this setting. Intriguing multimodality strategies, chiefly deployed for early-stage disease with the aim of maxi-
mizing the efficacy and duration of the response, are being explored and may become valid therapeutic options in the future. Ulti-
mately, striking a balance between the clinical gains of these combinations and possibly increased toxicity and reduced quality of life
will be necessary. The development of precision medicine and accurate biomarkers is fundamental to progress. Cancer
2016;000:000–000. VC 2016 American Cancer Society.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed and third most lethal cancer among men in Western countries.1 The
vast majority of patients present with localized disease.2 If they are treated adequately, most patients have a positive prognosis
and a 5-year survival rate approaching 100%.1 However, a proportion will eventually experience either local or distant recur-
rence. In addition, metastatic disease accounts for approximately 5% of new diagnoses.3 The mainstay of treatment for meta-
static PCa has been androgen-deprivation therapy (ADT) since Huggins and Hodges first pioneered castration therapy in
1941.4 Androgens, particularly testosterone and dihydrotestosterone, drive PCa growth. In the modern era, luteinizing
hormone-release hormone agonists (LHRHas) and antagonists are used to achieve a castrate level of serum testosterone (by
convention defined as a testosterone level< 50 ng/mL). Over the years, many debates have surrounded ADT: early initiation
versus deferred initiation, the addition of an androgen receptor (AR) antagonist for combined androgen blockade (CAB) ver-
sus monotherapy, LHRHas versus antagonists, and intermittent therapy versus continuous therapy. These issues will not be
discussed here because they are not the purpose of this review. It is known that 80% to 90% of patients will initially respond
both clinically and biochemically to ADT, and this translates into disease control for several years and improvements in
cancer-related symptoms.5 Nonetheless, hormone therapy is rarely curative, and in the metastatic setting, cancer typically
progresses within 2 to 3 years despite castrate levels of serum testosterone.5 This stage is known as castration-resistant prostate
cancer (CRPC) and, despite many more treatment options, commonly leads to death in 2 to 4 years.6
Recent breakthroughs in the understanding of the mechanisms of PCa adaptation to ADT, focusing on the AR path-
way, have demonstrated that PCa continues to be hormone-dependent even when evolving to castration resistance.7 This
concept allows a refined definition of untreated PCa, which is now termed castration-sensitive prostate cancer (CSPC).
This review outlines new developments and investigational strategies for the treatment of CSPC.
THE STATE OF THE ART
ADT can be administered by bilateral orchiectomy or medical castration with LHRHas or antagonists, and although both
approaches are equally recommended by the current National Comprehensive Cancer Network (NCCN) guidelines,3,8
the latter represents the most frequent choice in clinical practice.
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Lately, the addition of docetaxel to ADT for CSPC
has demonstrated a survival advantage, and it is now a val-
idated option for CSPC patients who are considered fit
for chemotherapy.3,8 An understanding of the heteroge-
neity of PCa cells9 provided the rationale for 2 large ran-
domized clinical trials that led to the practice change.10,11
Both the Chemohormonal Therapy Versus Androgen Ab-
lation Randomized Trial for Extensive Disease in Prostate
Cancer (CHAARTED) and the Systemic Therapy in Ad-
vancing or Metastatic Prostate Cancer: Evaluation of
Drug Efficacy (STAMPEDE) study tested 6 cycles of
docetaxel in addition to ADT versus ADT alone in CSPC
patients, and they demonstrated an unprecedented surviv-
al benefit in favor of the combination.10,11 CHAARTED
recruited only men with metastatic castration-sensitive
prostate cancer (mCSPC), whereas STAMPEDE also in-
cluded men with high-risk, locally advanced, and bio-
chemically recurrent disease. The overall survival (OS)
advantage for the metastatic subjects was 13.6 months
(hazard ratio [HR], 0.61; 95% confidence interval [CI],
0.47-0.80; P< .001) and 15 months (HR, 0.76; 95% CI,
0.62-0.92; P 5 .005) for the CHAARTED and STAM-
PEDE trials, respectively. In the former, patients were
stratified by the metastasis volume (high vs low): a high
volume was defined as 4 or more bone metastases with at
least 1 metastasis outside the spine and pelvis. The survival
benefit was highest in the high-volume cohort (17
months; HR, 0.60; 95% CI, 0.45-0.81; P< .001), where-
as in the low-volume cohort, the median OS was not
reached; longer follow-up is needed, with results expected
later in 2016. At present, the CHAARTED data suggest
that docetaxel plus ADT should be given only to patients
presenting with a high metastatic burden. In contrast, the
STAMPEDE study did not stratify by the volume of me-
tastases and achieved a remarkable OS benefit (15
months) for the whole metastatic population.
A meta-analysis of published randomized trials of
docetaxel plus ADT in men with mCSPC showed an im-
provement in the survival at 4 years of 9% (95% CI, 5%-
14%).12 The meta-analysis incorporated low-volume
metastatic patients and a smaller trial (GETUG-AFU 15).
The latter did not demonstrate a statistically significant
OS advantage, likely because of a lack of statistical pow-
er.13 In view of the available data, the updated NCCN
guidelines state that despite a less certain benefit for men
with lower volume disease, ADT plus docetaxel is recom-
mended for all adequately fit men with newly diagnosed
mCSPC, regardless of the disease burden.3,8 However,
until more data for low-volume metastatic patients (spe-
cifically long-term follow-up data from CHAARTED)
are available, we suggest careful consideration of the risks
and possible benefits of chemotherapy in this specific sub-
set of patients. Another caveat applies to men presenting
with metastases after the failure of local therapy: they were
a minority of participants in these trials in comparison
with subjects with newly diagnosed metastatic disease
who had not undergone prior local therapy.10,11 Because
the biology of these 2 divergent cancer presentations may
differ, it cannot be assumed that chemohormonal therapy
will yield equivalent survival benefits for all men with
mCSPC, and future trials should analyze these cohorts of
mCSPC patients separately.
Other compelling data from the STAMPEDE study
presented at the 2015 American Society of Clinical On-
cology (ASCO) meeting showed that the addition of 6
cycles of docetaxel to the standard of care (ADT 6
radiotherapy [RT]) for men with high-risk M0 PCa
resulted in failure-free survival benefits (HR, 0.60; 95%
CI, 0.45-0.80; P 5 .0003) in comparison with the stan-
dard of care (failure was defined as prostate-specific anti-
gen [PSA] failure or radiographic progression or death
due to PCa).14 These outcomes suggest that docetaxel in
combination with ADT and RT can be considered for
this subgroup of patients if they are deemed fit. However,
it should be noted that the OS data for this subgroup of
patients are not yet mature, and thus definitive recom-
mendations cannot be made. Also presented at the 2015
ASCO meeting were the results of the phase 3 Radiation
Therapy Oncology Group (RTOG) 0521 trial, which
randomized men with high-risk nonmetastatic PCa to re-
ceive ADT and RT with or without 6 cycles of adjuvant
docetaxel.15 The study described a OS benefit of 4%
(HR, 0.68; 95% CI, 0.44-1.03; 1-sided P 5 .03) and a 5-
year disease-free survival advantage of 7% (HR, 0.76;
95% CI, 0.57-1.00; 2-sided P 5 .05) in favor of the adju-
vant chemotherapy regimen. Notwithstanding criticisms
related to the small survival benefit achieved with doce-
taxel, the use of a 1-sided statistical analysis, and the pre-
maturity of the analysis (few deaths to date), the current
NCCN guidelines list this combination regimen as a valid
treatment option for high-risk nonmetastatic PCa
patients who are adequately fit.3,8 Notably, the demon-
strated activity of cabazitaxel in metastatic castration-
resistant prostate cancer (mCRPC)16 has also recently
prompted its investigation in this setting. The Swedish
ongoing phase 3 randomized trial SensiCab
(NCT01978873) seeks to assess the efficacy of cabazitaxel
in addition to ADT in patients with high-risk/N1/M1
PCa. The hypothesis is that this chemohormonal modali-
ty administered early, when the disease burden is null or
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minimal, could result in longer OS, progression-free sur-
vival (PFS), and PSA responses for this population.
NOVEL APPROACHES
PCa heterogeneity at all stages and the tendency of that
heterogeneity to increase throughout the disease course
have been demonstrated.9 This insight is fostering
renewed efforts to evaluate novel drugs and combination
regimens, and when these are deployed in the early stages
of PCa when the disease is less heterogeneous, these treat-
ments may provide higher and more durable responses
(Fig.F1 1).
ADT Combined With Second-Generation
Hormonal Agents
Novel AR axis–targeted drugs, particularly abiraterone ac-
etate (abiraterone) and enzalutamide, are being evaluated
at various stages of CSPC. The majority of these trials are
conducted “per industry agenda,” and there has not been
an overarching strategic development process based on a
biologic rationale. Abiraterone is a potent selective irre-
versible inhibitor of CYP17A1, a key enzyme in androgen
synthesis. Abiraterone is usually administered with pred-
nisone to prevent possible mineralocorticoid excess (here-
after prednisone will not be noted), whereas enzalutamide
is a next-generation AR antagonist that binds to AR in
competition with androgens and prevents AR transloca-
tion to the nucleus and its binding to DNA. Both abira-
terone and enzalutamide have demonstrated survival
benefits for men with mCRPC.17-20 The addition of these
drugs to gonadal ADT is postulated to effect a more
potent type of CAB and result in more efficient suppres-
sion of the AR-driven PCa growth pathway.21
Abiraterone- or Orteronel-Alone Trials (Table T11)
In the last 2 decades, several studies have investigated neo-
adjuvant ADT for men with early-stage PCa with the aim
of decreasing recurrence rates.22-24 A validated metric of
efficacy for neoadjuvant therapy combined with prosta-
tectomy does not exist. However, because local pathologi-
cal responses in other cancers (breast and bladder)
correlate with improved clinical outcomes,25 pathological
responses are also measured in PCa neoadjuvant trials.
Overall, despite significant decreases in positive surgical
margins, few pathological complete responses (pCRs) and
an overall lack of clinical benefit are described in these
reports.22-24 Tissue analyses of prostatectomy specimens
provided a partial explanation: they showed that an
LHRHa alone fails to elicit deep suppression of tissue an-
drogen levels.26 Abiraterone, irreversibly inhibiting
CYP17A1, potently suppresses androgen synthesis in all
tissues, including PCa tissue.21 In a recent phase 2 trial,
patients with localized high-risk PCa were randomly
assigned to receive an LHRHa with or without abirater-
one with a research prostate biopsy at 12 weeks and radical
prostatectomy (RP) at the end of 24 weeks of treatment.26
At 12 weeks, the abiraterone cohort showed significantly
lower levels of intraprostatic dihydrotestosterone
(P< .001) and testosterone (P< .05) in comparison with
the cohort receiving an LHRHa alone. At 24 weeks, a
10% pCR rate and a 14% minimal residual disease rate
TABLE 1. Ongoing Trials of Abiraterone or Orteronel (TAK-700) Alone
ClinicalTrials.gov Identifier Phase Eligibility Regimen Primary Endpoint Results
NCT01751451 2 BR after RP/RT Abiraterone vs abiraterone 1
degarelix vs degarelix
PFS Estimated complete in
October 2017
NCT01786265 2 BR after RP/RT Abiraterone 1 LHRH vs LHRH PSA-free survival Estimated complete in
February 2018
NCT01715285 3 Newly diagnosed
mCSPC
Abiraterone 1 ADT vs
placebo 1 ADT
OS and rPFS Estimated complete in
August 2018
NCT01957436 (PEACE1) 3 mCSPC Abiraterone 1 ADT 6
docetaxel 6 RT vs
ADT 6 docetaxel 6 RT
OS Estimated complete in
October 2023
NCT01546987 (RTOG 1115) 3 High-risk before RP Orteronel 1 LHRHa 1
RT 1anti-androgen vs
LHRHa 1 RT 1conventional
anti-androgen
OS Estimated complete in
June 2020
NCT01809691 (S1216) 3 Newly diagnosed mCSPC Orteronel 1 LHRHa vs
bicalutamide 1 LHRHa
OS Estimated complete in
July 2020
Abbreviations: abiraterone, abiraterone acetate plus prednisone; ADT, androgen-deprivation therapy; BR, biochemical relapse; LHRH, luteinizing hormone-
releasing hormone; LHRHa, luteinizing hormone-releasing hormone agonist; mCSPC, metastatic castration-sensitive prostate cancer; OS, overall survival;
PEACE1, Prostate Cancer Consortium in Europe 1; PFS, progression-free survival; PSA, prostate-specific antigen; RP, radical prostatectomy; rPFS, radio-
graphic progression free survival; RT, radiotherapy; RTOG, Radiation Therapy Oncology Group.
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(tumor 5 mm) for patients in the longer exposure
abiraterone-LHRHa group were observed. Although
some patients with high-risk disease demonstrated re-
markably good responses, others had residual high-
volume disease.26 The observed persistence of androgen
metabolites within the prostate tissue was postulated as a
possible mechanism of resistance for the combined regi-
men. Investigations of biomarkers of response and resis-
tance, including genomic analyses, are ongoing.
Interestingly, abiraterone was recently proven to have
direct bone antiresorptive and anabolic activity.27 There-
fore, with the aim of improving the management of bone
metastases and prolonging the time to castration resistance,
abiraterone therapy is being evaluated for mCSPC. A ran-
domized phase 3 trial (NCT01715285) is examining the
survival benefit of the combination of abiraterone and
ADT versus ADT plus a placebo in men with newly diag-
nosed mCSPC, and similar studies are ongoing (Table 1).
Furthermore, orteronel (TAK-700), a reversible nonsteroi-
dal selective inhibitor of 17,20-lyase and thus of androgen
synthesis, is being investigated in the same setting. Ortero-
nel, despite showing antitumor activity, failed to demon-
strate an OS advantages in CRPC.28,29 In the phase 3 trial
S1216 (NCT01809691), orteronel in addition to an
LHRHa for more potent CAB is compared with an
LHRHa plus bicalutamide with OS as the primary out-
come. Positive outcomes could suggest its use in mCSPC.
Enzalutamide- or Apalutamide-Alone Trials
(TableT2 2)
Many trials have demonstrated that the addition of con-
comitant and adjuvant ADT to RT is beneficial for the
treatment of localized PCa.30 Subsequently, the possible
application of novel AR-targeted agents, particularly enza-
lutamide, in this setting has garnered much interest. In a
phase 3 trial by the Australian and New Zealand
Urogenital and Prostate Cancer Trials Group (Enzaluta-
mide in Androgen Deprivation Therapy With Radiation
Therapy for High Risk, Clinically Localised, Prostate
Cancer [ENZARAD]; NCT02446444), patients with
high-risk localized disease are randomized to receive RT
with an LHRHa plus enzalutamide or a conventional
anti-androgen. The primary outcome is OS, and other
relevant endpoints are the cause-specific survival time,
biochemical and clinical PFS, and metastasis free-survival
time. In addition, an ongoing phase 2 study
(NCT02028988) is evaluating the efficacy (PSA re-
sponse) of noncastrating therapy with enzalutamide alone
for 6 months plus RT for intermediate-risk PCa patients.
Moreover, enzalutamide is being explored in
mCSPC (Table 2). A multicenter, randomized phase 3
trial (Enzalutamide in First Line Androgen Deprivation
Therapy for Metastatic Prostate Cancer [ENZAMET];
NCT02446405) seeks to compare OS and biochemical
and clinical PFS with ADT plus enzalutamide versus
ADT plus a conventional anti-androgen. Because enzalu-
tamide has been proven both in vitro and more recently in
vivo in mCRPC to be a more potent AR blocker and have
no AR agonist activity in comparison with bicalutamide,
the hypothesis is that enzalutamide will further reduce AR
signaling and thus improve outcomes.31-33
In addition, the second-generation AR antagonist
apalutamide (ARN-509) showed greater potency than
first-generation AR inhibitors such as bicalutamide in pre-
clinical models,34 and it is currently being tested for
TABLE 3. Ongoing Trials of Combinations of Novel Androgen Receptor Axis–Targeted Agents
ClinicalTrials.gov







pCR and MRD rates Estimated complete in
February 2022
NCT02789878 2 High-risk localized
before RP
Abiraterone 1 goserelin 1
apalutamide vs
abiraterone 1 goserelin
pCR and pnCR Estimated complete in
October 2019
NCT02772588 2 Very high-risk localized Abiraterone 1
apalutamide 1
leuprolide 1 RT
BR rate Estimated complete in
May 2018
NCT02799602 (ARASENS) 3 mCSPC Darolutamide (ODM-201) 1
ADT 1 docetaxel vs
placebo 1 ADT 1 docetaxel
OS Estimated complete in
January 2022
Abbreviations: abiraterone, abiraterone acetate plus prednisone; ADT, androgen-deprivation therapy; ARASENS, ODM-201 in Addition to Standard ADT and
Docetaxel in Metastatic Castration Sensitive Prostate Cancer; BR, biochemical relapse; mCSPC, metastatic castration-sensitive prostate cancer; MRD, mini-
mal residual disease; OS, overall survival; pCR, pathological complete response; pnCR, pathological near complete response; RP, radical prostatectomy; RT,
radiotherapy.
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mCSPC as well as other stages of the disease (Table 2).
The randomized phase 3 trial TITAN (NCT02489318)
is assessing the efficacy of the combination of apalutamide
and ADT versus ADT plus a placebo in patients with low-
volume mCSPC. Positive results could provide a new
treatment option for this specific subgroup of patients.
AR Axis Combination Trials
The need for improving AR-directed tumor growth inhibi-
tion led to the investigation of combinations of hormonal
agents (TableT3 3). In preclinical models of CRPC xenografts,
abiraterone exposure in some cases resulted in increased ex-
pression of AR, CYP17, and other key enzymes pivotal for
testosterone synthesis.35 Thus, the combination of a potent
AR antagonist with abiraterone may inhibit de novo ste-
roidogenesis in the tumor and thus result in more effective
therapy. To test this hypothesis, a randomized phase 2 trial
(NCT02268175) is currently recruiting intermediate- and
high-risk PCa patients for enzalutamide and leuprolide with
or without abiraterone before RP. The efficacy of this com-
bination of second-generation hormonal agents is being
assessed in terms of pCR and minimal residual disease rates,
and the trial includes an analysis of the bone marrow as a
niche for resistant tumor clones. Recently, the results of a
similar phase 2 trial that randomized high-risk PCa patients
to receive abiraterone and an LHRHa with or without enza-
lutamide before RP were reported (ASCO 2016). The inci-
dence of pathological downstaging (pT2N0) was lower
(30% vs 52%; P 5 .07) and the detection of androgen-
receptor splice variant 7 was more frequent in the combina-
tion arm (enzalutamide plus abiraterone and an LHRHa)
than the arm receiving abiraterone plus an LHRHa. These
data indicate that the addition of enzalutamide to an
LHRHa plus abiraterone was not effective in this trial.
However, further investigation of the utility of more intense
ADT is needed before any definite conclusions are drawn.36
Finally, a new generation of AR pathway–targeted
agents is going through clinical development.37-39 Daro-
lutamide (ODM-201) is a novel nonsteroidal anti-
androgen that in vitro showed greater potency and a
higher affinity for AR than enzalutamide and negligible
penetrance of the blood-brain barrier.40 VT-464 and
CFG920 are novel CYP17 inhibitors in early stages of de-
velopment. Lastly, EPI-001 and its successor EPI-506 are
first-in-class selective inhibitors of the N-terminal domain
of the AR and thereby promise to be effective against ca-
nonical and aberrant AR splice variants. Especially if prov-
en effective against CRPC, some of these agents are likely
to be evaluated also for CSPC in the near future. In this
respect, a multicenter, randomized phase 3 trial investigat-
ing darolutamide in mCSPC (ODM-201 in Addition to
Standard ADT and Docetaxel in Metastatic Castration
Sensitive Prostate Cancer [ARASENS]; NCT02799602)
was recently started (Table 3).
TABLE 4. Ongoing Trials of Chemotherapy Plus ADT






















NCT00348816 2 BR after RP Docetaxel 1 RT PSA decline and PSA
nadir (0 ng/mL rate)
Estimated complete in
December 2016
NCT02543255 (ACDC-RP) 2 High-risk before RP Cabazitaxel 1
abiraterone 1 leuprolide vs
abiraterone 1 leuprolide
pCR Estimated complete in
October 2018
NCT01952223 (PEACE2) 3 High-risk localized
before RP/RT
Cabazitaxel 1 ADT 1
prostate RT vs ADT 1
prostate RT vs
cabazitaxel 1 ADT 1
pelvic RT vs ADT 1
pelvic RT
PFS Estimated complete in
September 2026
NCT01978873 (SensiCab) 3 High-risk/N1/mCSPC Cabazitaxel 1 ADT vs ADT OS Estimated complete in
November 2019
Abbreviations: abiraterone, abiraterone acetate plus prednisone; ACDC-RP, Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy;
ADT, androgen-deprivation therapy; BR, biochemical relapse; CALGB, Cancer and Leukemia Group B; LHRHa, luteinizing hormone-releasing hormone agonist;
mCSPC, metastatic castration-sensitive prostate cancer; OS, overall survival; pCR, pathological complete response; PEACE2, Prostate Cancer Consortium in
Europe 2; PFS, progression-free survival; PSA, prostate-specific antigen; PUNCH, Preoperative Use of Neoadjuvant Chemohormonal Therapy; RP, radical
prostatectomy; RT, radiotherapy.
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ADT Combined With Chemotherapy
A plausible reason for the lack of a survival benefit from
ADT-only neoadjuvant therapy is that androgen-
independent stem cells may already be present at early
stages of the disease, and under the selective pressure
exerted by ADT, the growth and spread of systemic
micrometastases are possible.9,41 Over the years, several
phase 1/2 studies have evaluated the efficacy of neoadju-
vant chemotherapy; they have frequently achieved favor-
able PSA declines and statistically significant rates of
tumor reduction and negative surgical margins.42,43 How-
ever, these reports are quite heterogeneous with respect to
the cytotoxic agent and dosage used, the analysis of patho-
logical outcomes, the primary outcomes evaluated, and
the duration of follow-up.43 Most importantly, none of
these studies have reported pCR rates. Therefore, because
neither neoadjuvant ADT nor chemotherapy alone seems
to result in improved clinical outcomes, combination reg-
imens of chemotherapy plus ADT have been tested in
multiple studies44,45 and are the focus of ongoing research
(TableT4 4). The vast majority of these trials have investigat-
ed some combination of docetaxel and hormonal therapy
as neoadjuvant treatment before RP. In the largest phase 2
study, which was led by the Canadian Urologic Oncology
group, CAB and docetaxel were given to high-risk patients
before RP. Overall, the treatment was well tolerated, and
a median PSA decrease before surgery of 98.4% and a
pCR rate of 3% were reported.46 In a contemporary, mul-
ticenter phase 3 trial (Groupe d’Etude des Tumeurs
Urogenitales [GETUG]) GETUG-12, patients with
high-risk localized or N1 disease randomly received an
LHRHa plus or minus docetaxel and estramustine. After a
median follow-up of 8.8 years, the rate of recurrence-free
survival (RFS), which included biochemical, local, and
distant relapse, was 62% (95% CI, 55%-69%) in the
ADT-chemotherapy group and 50% (95% CI, 44%-
57%) in the ADT-alone group.47 However, because most
relapses were biochemical, it has not been ascertained
whether the described RFS benefit will translate into an
improvement of clinically significant long-term out-
comes. Furthermore, per the study design, all patients
underwent staging pelvic lymph node dissection after 3
months of treatment, and even though 71% of the
patients were N0, the vast majority received RT instead of
RP.47 Therefore, caution should be used in applying these
findings to the neoadjuvant prostatectomy setting. Be-
cause of the conflicting body of findings between prosta-
tectomy pathological endpoints and long-term outcomes,
the current NCCN guidelines do not recommend the use
of neoadjuvant therapy for patients with localized or
locally advanced PCa. For this reason, there is anticipation
for the results of a multicenter, randomized phase 3 trial
(Cancer and Leukemia Group B [CALGB]/Alliance
90203/Preoperative Use of Neoadjuvant Chemohormonal
Therapy [PUNCH; NCT00430183) comparing the effica-
cy of 6 cycles of docetaxel in addition to an LHRHa fol-
lowed by RP with the efficacy of immediate RP alone for
high-risk PCa patients. Results are expected in 2017, and
genomic analyses to detect differences between chemohor-
monal responders and nonresponders are under way. Lately,
just as for other agents demonstrating survival benefits for
mCRPC patients, there is interest in testing the taxane caba-
zitaxel16 in the neoadjuvant setting. A 4-arm phase 3 trial
(Prostate Cancer Consortium in Europe 2 [PEACE2];
NCT01952223) seeks to evaluate the efficacy of ADT and
prostate RT plus or minus cabazitaxel or ADT and prostate
and pelvic RT plus or minus cabazitaxel, which are being
randomly assigned to men with high-risk disease. These
prospective, randomized trials have the potential to change
the therapeutic approach to high-risk localized PCa patients
by validating the use of neoadjuvant therapy.
Because chemotherapy is postulated to target the
androgen-independent cancer clones, which are possibly the
cause of distant relapse, assessing chemohormonal therapy
in the adjuvant setting is equally rational. Docetaxel and RT
may have a synergistic effect because they both induce cell
cycle arrest and apoptosis in the G2 and M phases.48,49 In
this respect, the preliminary results of RTOG 0621, a
single-arm phase 2 trial of patients with high-risk features
treated after surgery with RT plus ADT and docetaxel, were
reported at the 2014 ASCO meeting. The rate of freedom
from progression (defined as a PSA level< 0.4 ng/mL and
no clinical failure or death from any cause) at 3 years was
71% (95% CI, 61%-81%; P< .001).50 Although these
results seem interesting, at the moment, phase 3 trials are
scarce, and enrollment represents a major challenge in this
setting. In this regard, the contemporary Veterans Affairs
Cooperative Studies Program 553 trial (NCT00132301) is
evaluating the efficacy of 6 cycles of docetaxel versus surveil-
lance until biochemical recurrence (BR) for RP-treated
patients with a high risk of relapse. Positive results could po-
tentially lead to extending the chemohormonal approach to
the post-RP adjuvant setting.
Similarly, in the past, several phase 2 trials have sug-
gested a possible benefit of chemotherapy with hormone
therapy in the BR stage.51-53 Taplin et al51 conducted a
phase 2 study of men with BR treated with docetaxel and
estramustine and 18 months of CAB. After a median of 5
years of follow-up and with recovered testosterone, 11%
of the subjects had PSA levels< 0.1 ng/mL, and 24% had
J_ID: CNCR Customer A_ID: CNCR30329 Cadmus Art: CNCR30329 Ed. Ref. No.: 16-1123.R1 Date: 22-October-16 Stage: Page: 8
ID: jwweb3b2server Time: 00:36 I Path: D:/Wiley/Support/XML_Signal_Tmp_AA/JW-CNCR160343
Review Article
8 Cancer Month 00, 2016
not reinitiated ADT.52 In a similar fashion, noting that
angiogenesis may have a key role in PCa growth and me-
tastasis,54 a phase 2 trial explored the benefits of early
multimodality systemic therapy with the antiangiogenic
drug bevacizumab in addition to chemohormonal treat-
ment for men with BR. After a median follow-up of 27.5
months, 20% of men were BR-free, and 46% had not
restarted ADT.53 Although phase 2 data are promising,
phase 3 trials are needed to confirm the overall benefits of
chemohormonal therapy in the BR setting.
Finally, the recent progress made in the field of next-
generation sequencing has resulted in an improved under-
standing of the genomic landscape of PCa. In particular,
recent genomic analyses have demonstrated that approxi-
mately 20% of patients with mCRPC have somatic muta-
tions in DNA repair genes (DRGs), including BRCA1,
BRCA2, ATM, FANCA, RAD51B, and RAD51C.55 The
DRG somatic mutation rate is lower in localized PCa ver-
sus mCRPC at approximately 8% (The Cancer Genome
Atlas), but the prevalence may be higher in select popula-
tions and in patients with very high-risk disease. In addi-
tion, the prevalence in mCSPC is not known but is under
investigation.56 The rate of DRG germline aberrations in
mCRPC is as high as 11%, and this may also be found in
high-risk patients with earlier stages of CSPC.57 Although
the prognostic implications of this finding are still un-
clear, a recent study suggested that BRCA2 germline mu-
tation carriers are more frequently associated with
metastases at diagnosis, a Gleason score 8, a T3/4 stage,
and significantly shorter 5-year metastasis-free survival for
those subjects with localized PCa.58 However, it is known
that patients with DRG mutations frequently respond to
platinum therapy (cisplatin and carboplatin) and to poly(-
adenosine diphosphate ribose) polymerase (PARP) inhibi-
tors; this provides an opportunity to evaluate these
therapies in both CRPC and CSPC.59,60
A phase 2 trial of the PARP inhibitor olaparib in ad-
vanced CRPC (Phase II Trial of Olaparib in Patients
With Advanced Castration Resistant Prostate Cancer
[TOPARP]) revealed that 88% of the 16 patients found
with DRG alterations, including BRCA1/2, Fanconi ane-
mia genes, ATM, and CHEK2, responded to olaparib.60
This study served as a proof of concept of the efficacy of
PARP inhibitors in mCRPC, and it also suggested that
the subset of patients who may be sensitive to PARP
inhibitors or platinum therapy is not limited to BRCA1/2
aberrations and most likely also includes somatic muta-
tions in genes involved in the homologous recombination
pathway. Such mutations may be responsible for func-
tional defects similar to those of BRCA-mutated tumors
(BRCAness); this would explain the sensitivity to PARP
inhibitors and platinum. In the future, once validated
through prospective clinical trials, a large BRCAness panel
could be used as a biomarker of responsiveness to plati-
num therapy and PARP inhibitors and thereby allow pre-
cision medicine. Furthermore, the TOPARP study laid
the basis for further evaluations of olaparib in earlier stages
of the disease and in combination with other agents. For
CSPC, a phase 1 study of men with intermediate/high-
risk disease before RP (NCT02324998) is assessing the
feasibility of degarelix with or without olaparib.
The field of genomics and PCa is rapidly evolving,
and in the context of CSPC, we recommend that genomic
sequencing analysis be considered in men with a family
history of PCa and in men with a young or very aggressive
presentation of PCa. In addition, we deem that when men
with CSPC harbor DRG abnormalities, despite the lack
of prospective data, platinum therapy or PARP inhibitors
with ADT can be considered (preferably in a trial).
ADT Combined With Bone-Targeted Therapies
Samarium 153 (Sm153) and radium 223 (Ra223) are ra-
diopharmaceutical b and a emitters, respectively, devised
to selectively bind to hydroxyapatite in the bone and
thereby result in irradiation of osteoblastic metastases
with minimal effect on surrounding normal tissue. Ra223
demonstrated a survival benefit in mCRPC.61 These find-
ings provide support for investigating these compounds in
nonmetastatic CSPC patients in hopes of prolonging the
time to metastatic disease. The ongoing phase 2 study
RTOG 0622 (NCT00551525) is exploring the safety and
efficacy of Sm153 given to post-RP N0/N1 patients with
BR, whereas a multicenter, randomized phase 2 trial
(NCT02656563) is seeking to assess the efficacy of Ra223
in prolonging the off-treatment interval for men with BR
who have received 6 to 8 months of intermittent ADT.
Furthermore, an ongoing randomized phase 2 study
(NCT02582749) is testing Ra223 with or without ADT
for men with newly diagnosed mCSPC. Positive results
could lead to a phase 3 trial.
Long-term ADT is associated with a loss of bone
mineral density and weight gain, which increase the inci-
dence of fractures in men with PCa.62,63 Along with calci-
um and vitamin D supplementation, bisphosphonates
(particularly zoledronic acid) and the anti–receptor activa-
tor of nuclear factor jB ligand antibody denosumab
should be considered for mCRPC patients undergoing
ADT according to the fracture risk.63,64 These com-
pounds have also been proven to decrease bone pain and
the rate of skeletal-related events in patients with osseous
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mCRPC.65,66 In the recent multicenter phase 3 trial
CALGB 90202 (Alliance), zoledronate, randomly admin-
istered to patients with mCSPC, showed no skeletal-
related events or OS benefit.67 Similarly, the STAM-
PEDE trial reported no survival advantage for the combi-
nation of zoledronate and standard of care plus or minus
docetaxel for men with high-risk, locally advanced, recur-
rent or metastatic disease.10 Therefore, these bone-
targeted therapies are not recommended in this setting ex-
cept for treating osteoporosis. However, it should be not-
ed that denosumab has not been assessed for mCSPC yet.
ADT Combined With Immunotherapy
Another intriguing and developing chapter in the treat-
ment of PCa is immunotherapy.
Because the neoadjuvant setting provides the oppor-
tunity to observe the effects of a compound at the tissue
level and could ultimately serve as a proof of principle,
several experimental immunotherapeutic drugs are cur-
rently being explored at this stage as single agents or in
combination (TableT5 5). GVAX-PCa is a cellular vaccine
comprising a mixture of 2 irradiated allogeneic PCa cell
lines genetically modified to produce granulocyte-
macrophage colony-stimulating factor. An interesting
phase 2 trial studied the effects of the combination of
GVAX and docetaxel in patients undergoing RP. No
pCRs were observed; however, downstaging of the Glea-
son score (significance unknown) was observed in 4 of 6
men after RP.68 In addition, a phase 1/2 trial
(NCT01696877) is currently evaluating the combination
of GVAX and degarelix before RP (Table 5).
Moreover, the investigation of ipilimumab, a human
monoclonal antibody that binds to cytotoxic T-
lymphocyte antigen 4 and inhibits the downregulation of
T-cell activation, in CSPC is also ongoing. Although pre-
clinical studies supported its antitumor activity in PCa,69
the subsequent phase 1/2 studies of ipilimumab in
mCRPC yielded quite disappointing results.70,71 Further-
more, in a randomized phase 3 trial of patients with
mCRPC progressing after docetaxel, ipilimumab after RT
showed no statistically significant OS difference in com-
parison with a placebo.72 However, a subgroup analysis of
patients with favorable prognostic features demonstrated
a significantly improved survival advantage in comparison
with a placebo, and interestingly, the trend was for
achieved objective responses to be sustained over the long
term.72 Therefore, ipilimumab is currently being investi-
gated in combination with an LHRHa before RP for men
with high-risk PCa in a phase 2 trial (NCT01194271).
Moreover, a phase 2 study (NCT02020070) is analyzing
the safety and efficacy of the multimodality approach of
ipilimumab plus degarelix in men with newly diagnosed
oligometastatic disease before and after RP and in men
with postsurgical biochemical or distant relapse. Finally, a
phase 2 trial (NCT02506114) will evaluate the
CD3 1 T-cell immune response to ipilimumab or
Prostvac-VF, a recombinant virus vector vaccine contain-
ing the genes for human PSA and 3 costimulatory mole-
cules, in men with localized PCa before surgery. In this
respect, Prostvac-VF is being tested also in several ongoing
trials (Table 5).
Despite these trials, immunotherapy for CSPC
remains a preliminary approach for which biomarkers and
clinical endpoints of efficacy are still needed.
Nonhormonal Approaches With or Without
Standard ADT
Preclinical data support the evaluation of a variety of non-
hormonal agents in early PCa. In this respect, compounds
directed at serum vascular endothelial growth factor and
various other tyrosine kinase inhibitors have been and are
being investigated in PCa clinical trials and might emerge
as future therapeutic options for CSPC. In particular, be-
cause tumors cannot grow more than 1 to 2 mm without
developing neovasculature,73 exploiting antiangiogenetic
drugs has become an ongoing focus, and trials include
evaluations of bevacizumab (NCT00776594), sunitinib,
and cabozantinib. In this regard, despite the negative
results achieved in mCRPC,74,75 the combination of
cabozantinib and ADT is being tested in a phase 2 study
(NCT01630590) of men with mCSPC with PFS as the
main outcome measure.
Furthermore, the antidiabetic oral drug metformin
is being actively analyzed for various stages of CSPC
(NCT01620593 and NCT02420652). The rationale
stems from the demonstration in vitro of an antiprolifera-
tive effect of metformin and from the observation of ADT
being associated with metabolic syndrome, insulin resis-
tance, and hyperinsulinemia. The latter stimulates insulin
receptor expression on PCa and possible tumor growth.
Metformin has been shown to reduce insulin levels and
also to inhibit the mammalian target of rapamycin
pathway.76
In addition, several agents that target specific cancer
genotypes and have shown promising results in preclinical
studies are being or could soon be investigated in clinical
trials of CSPC. In particular, because both SRC and
mitogen-activated protein kinase kinase/extracellular
signal-regulated kinase signaling pathways have been
shown to be upregulated in CRPC,77,78 a neoadjuvant
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phase 2 trial (NCT01990196) is comparing the effects of
the AR inhibition of degarelix plus enzalutamide with or
without the SRC inhibitor dasatinib or the mitogen-
activated protein kinase kinase inhibitor trametinib. Fur-
thermore, the pan-AKT inhibitor AZD5363 has shown ef-
ficacy in mouse models of phosphatase and tensin
homolog–deficient PCa. Because the PI3K/AKT pathway
is frequently altered in advanced PCa, mainly because of
the functional loss of phosphatase and tensin homolog, this
protein is a potential target for personalized therapy.79 We
envisage that the outcomes of these and future trials as well
as the broad availability of commercial next-generation
DNA sequencing will eventually lead to routine genomic
screening of PCa patients to identify actionable mutations
and inform optimal individualized therapy.
In conclusion, although ADT remains the corner-
stone of CSPC therapy, PCa heterogeneity supports the
investigation of chemotherapy, novel AR axis–targeted
agents, and other pathway inhibitors in CSPC. In particu-
lar, multimodality approaches are being actively explored
and are likely to generate future treatment advances.
Moreover, these strategies will be explored in the early
stages of disease with the aim of maximizing the efficacy
and duration of the response. However, striking a balance
between the clinical benefits of earlier therapy and in-
creased toxicity and cost will become paramount. To this
end, developing biomarkers and precision medicine is a
fundamental step toward extending the benefits and re-
ducing the risks of ineffective therapy.
Finally, the advances of genomics and immunother-
apy are translating into a multitude of experimental
approaches, and ongoing and future trials will explore
their efficacy in CSPC patients.
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0000 Prostate Cancer: Developing Novel Approaches to Castration-Sensitive Disease
Edoardo Francini, and Mary-Ellen Taplin
Multimodality approaches including chemotherapy and novel hormonal agents are frequently investigated in early-stage
prostate cancer with the aim of maximizing the response efficacy and duration for patients with castration-sensitive disease.
Immunotherapy and experimental molecules are also being actively explored in this setting.
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